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1. Introduction
Snake venoms contain a complex mixture of proteins and biologically active peptides [1, 2].
Some of these bioactive peptides are derived from precursor proteins that through proteo‐
lytic processing generate mature active polypeptides [3]. As an example, the protein precur‐
sor of natriuretic peptide type-C (CNP) from the Brazilian pit viper Bothrops jararaca venom
and brain originates CNP, a hormone present in several animal species as well as various
isoforms of proline-rich oligopeptides (Bj-PROs) [4, 5]. Bj-PROs were the first natural inhibi‐
tors of angiotensin I-converting enzyme (ACE) described [6]. The metalloproteinase ACE,
the key enzyme of the renin-angiotensin system, displays two homologous active sites, one
at the C-terminal and the other at the N-terminal of the protein [7]. While both active sites
convert angiotensin I into angiotensin II and cleave bradykinin (BK) into BK1-5 and BK1-7,
the C-terminal is more effective in hydrolysis of these vasoactive peptides [8].
Bj-PROs are molecules of 5 to 14 amino acids residues with a pyroglutamyl residue (<E) at
the N-terminus and a proline residue at the C-terminus. Bj-PROs longer than seven amino
acids share similar features, including a high content of proline residues and a C-terminal
tripeptide sequence Ile–Pro–Pro [13]. Since Bj-PROs are ACE inhibitors, they potentiate
some pharmacological activities of BK, such as induction of contractile action of smooth
muscles of guinea-pig ileum in vitro as well as in vivo BK-induced effects on central nervous,
cardiovascular and anti-nociceptive systems [6, 9, 10]. For this reason, these peptides were
initially named bradykinin-potentiating peptides (BPPs). The ability of some Bj-PROs inhib‐
iting ACE turned them in structural models to develop the first non-peptide site directed in‐
hibitor of this enzyme. The development of Captopril in the early 1980s became a paradigm
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for “rational drug design”, a concept much heralded today and made possible by computer
imaging and genome science [11].
Many studies on structure–activity of Bj-PROs showed that a simple analogous structure to
Ala–Pro was optimal for binding to the active site of ACE. Replacement of the carboxyl by a
sulfhydryl group enhanced the inhibitory activity of the analogue by 1,000-fold. This com‐
pound proved to be one of the most potent competitive inhibitors of ACE and, therefore,
turned into a useful drug to treat human hypertension (reviewed by [12]). Captopril was a
blockbuster drug and inspired the creation of several generations of similar antihyperten‐
sive compounds.
However, due to structural diversity of Bj-PROs [13] other mechanisms besides inhibiting
ACE were proposed. In fact, some of these peptides augmenting argininosuccinate synthase
(AS) activity in vitro and in vivo, can also induce rises in free intracellular calcium concentra‐
tion ([Ca2+]i) by acting on muscarinic acetylcholine, BK or yet unidentified receptors [15-18]
or reversal inhibition of nicotinic acetylcholine receptor [19]. These novel mechanisms of ac‐
tion, recently identified for Bj-PROs explain their anti-hypertensive effects [14-17, 20, 21].
Therefore, investigation of Bj-PRO-induced effects through acting on different targets opens
possibilities of applications for these peptides in the treatment of several pathologies lacking
efficient treatment options.
Here, we describe the targets of various Bj-PROs and their potential use to treat different
target-related pathologies, as well as discuss chemical properties of these peptides for ob‐
taining an oral pharmaceutical formulation.
2. Targets of proline-rich oligopeptides from Bothrops jararaca
Recently, argininosuccinate synthase (AS) was identified as another target for the Bj-PROs,
which both in vitro and in vivo positively modulates the activity of this enzyme [14] which
leads to L-arginine synthesis [22]. L-arginine is a nonessential amino acid under normal con‐
ditions as it is obtained from the breakdown of proteins or synthesized de novo from citrul‐
line in the kidneys by AS (EC 6.3.4.5) and argininosuccinate lyase (ASL, EC 4.3.2.1). AS
catalyses the reversible condensation of citrulline with aspartate with consumption of ATP
to form argininosuccinate; ASL catalyzes the conversion of the argininosuccinate to fuma‐
rate and L-arginine, which is released into the circulation [22].
In the liver, enzymes involved in the anabolism of L-arginine, AS and ASL are present; how‐
ever, there is not a net production of L-arginine due to arginase activity (EC 3.5.3.1) as part
of the urea cycle, catalyzes the hydrolysis of L-arginine into L-ornithine and urea. The urea
is then excreted in the urine and L-ornithine is recycled back into the cycle [23]. Further‐
more, AS is the rate-limiting enzyme of the citrulline-nitric oxide (NO) cycle for the supply
of L-arginine which is then metabolized by NO synthase (NOS) to form NO and citrulline
[24-26]. Citrulline, through the reactions catalyzed by AS and ASL may cycle back to argi‐
nine, constituting the citrulline-NO cycle [27, 28]. In summary, AS activity contributes to
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three major different functions in the adult organism depending on the cell/tissue consid‐
ered: (i) ammonia detoxification in the liver, (ii) L-arginine production for the whole organ‐
ism by kidney and (iii) L-arginine synthesis for NO production in many other cells [22].
Three isoforms of NOS catalyze the reaction: the endothelial constitutive NOS (eNOS), the
neuronal constitutive NOS (nNOS) and the inducible NOS (iNOS), reviewed in [29, 30]. NO
is a gaseous molecule capable of interacting with many intracellular targets for triggering a
series of signal transduction pathways, resulting in a stimulatory and inhibitory signals. NO
plays roles in cardiovascular, immune and neuronal control. It is directly involved in arterial
tension control since it regulates the local and systemic resistance of vascular walls, as well
as the sodium balance [31]. The NO produced by endothelial cells reaches neighboring
smooth muscle cells where it activates two types of K+ channels, ATP-sensitive and Ca2+-de‐
pendent [32, 33], and thereby induces the relaxation of blood vessels and brings about vas‐
cular dilation leading direct consequences in processes like erection, arterial pressure
systemic or organ-specific [34].
Due to the great physiological importance of the NO, compounds revealing properties aspo‐
tential NO donors have been protected by patents. They are based on the fact that there are
many pathological states related to NO deficiency (reviewed by [35]). However, a major
problem of NO donors is to achieve a therapeutic dose without reaching a threshold of tox‐
icity. Mostly, if NO is produced in excess around of cells in a pro-oxidant state, NO could
react with reactive oxygen species (ROS) such as superoxide and hydrogen peroxide form‐
ing peroxynitrite and nitrogen oxide III, which has been linked to pathogenesis of neurode‐
generative disorders [35].
The superoxide anion is produced by uncoupling of NOS due to the lack of its natural sub‐
strate L-arginine or tetrahydrobiopterin (BH4) [36], an important cofactor for NOS. Excessive
production of superoxide is explained by increased activity and expression of the enzyme
arginase, which competes with eNOS for its substrate L-arginine [37]. Other possible sources
for elevated concentrations of ROS include increased expression and activity of NADPH
and reduced superoxide dismutase activity [38, 39].
In order to compensate for the deficiency of NO production without induction of toxicity,
addition of exogenous L-arginine in the maintenance of NO production has been investigat‐
ed. The inefficiency of swallowed L-arginine in promoting increase of NO can be explained
by its low availability, due to the first pass effect, since the viability of L-arginine as sub‐
strate for NOS is reduced by the activity of arginase in the liver. Several studies have shown
that induction or activation of arginase may lead to impaired NO production and endothe‐
lial dysfunction (reviewed by [35]).
Thus, NO presents challenges and opportunities to intervene and promote human health.
The study of regulation of NO production becomes important for understanding the mecha‐
nisms which maintain NO levels in a safe range and not injurious to the body.
An important mechanism for control and maintenance of NO levels is achieved by its recy‐
cling via the NO-citrulline cycle. The obtained L-arginine provided by the citrulline-NO cy‐
cle is then directed to sustain NO production, sparing bulk intracellular L-arginine for other
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metabolic roles [24]. In view of that, compounds that increase AS activity and sustain tightly
NO production avoiding an excess production will ensure adequate bioavailability for prop‐
er physiological functioning. Guerreiro and colleagues demonstrated that a Bj-PRO pro‐
motes activation of AS, assayed in the presence of the substrates ATP, citrulline, and
aspartate, thus leading to NO production by endothelial cells [14]. More recently, we have
demonstrated that other Bj-PROs induce NO production by activation of AS or kinin-B2 re‐
ceptors as well as by M1 muscarinic acetylcholine activation, thereby inducing vasodilata‐
tion in vivo [16, 17].
The patent entitled “Proline-Rich Peptides, Pharmaceutical Composition, use of one or more
peptides and method of treatment” was deposited to protect the use and application of Bj-
PROs and analogous molecules [patent: BR2007/ 000003]. All applications contemplated by
patent BR2007/ 000003 are consistent with the use of PROs as prototype molecules for the
development of new drugs aiming to treat a range of pathological states related to deficien‐
cy in NO production and AS activity, e.g. lung hypertension, preeclampsia, essential hyper‐
tension, coagulopathies and citrullinemia. Some of these applications will be discussed
below.
3. Pulmonary hypertension
Pulmonary hypertension (PH) is an increase in blood pressure in the pulmonary artery, vein
or capillaries, together known as the lung vasculature. In fetus life, PH is a normal state es‐
sential for survival. Since the placenta, not the lung, serves as the organ of gas exchange dur‐
ing embryonic development, most of the right ventricular output crosses from the ductus
arteriosus to the aorta, and only 5–10% of the combined ventricular output is directed to the
pulmonary vascular bed. Pulmonary vascular constriction plays a key role in maintaining
high pulmonary vascular tone during fetal life. At the same time, the fetal lung and pulmo‐
nary vasculature must prepare for the dramatic adaptation to air breathing at the time of
birth [40].
However, PH can continue even after the birth, called persistent pulmonary hypertension
that develops when pulmonary vascular resistance remains elevated, resulting in right-to-
left shunting of blood through fetal circulatory pathways. The pulmonary vascular resist‐
ance may remain elevated due to pulmonary hypoplasia and cause disease states, like
congenital diaphragmatic hernia, as well as impaired development of the pulmonary arter‐
ies, resulting in the meconium aspiration syndrome, or failing adaption of the pulmonary
vascular bed as occurs with perinatal asphyxia [41]. Moreover, PH has more than one etio‐
logical factor, thus it can be classified as idiopathic PH when there is no identifiable cause of
this disease; familial PH with a previous disease history; and associated PH when an under‐
lying cause of PH such as connective tissue disease is present [42].
PH has been reported in patients with chronic hemolytic anemias, including sickle cell dis‐
ease, thalassemia, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis, malaria,
among other disease states [43, 44]. The exact mechanism(s) involved in the development of
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PH in these patients is unclear. Hemolysis may result in a nitric oxide deficient state
through free hemoglobin scavenging of nitric oxide and release of erythrocyte arginase,
which limits L-arginine, a substrate for nitric oxide synthesis [45].
Nitric oxide is synthesized from terminal nitrogen of L-arginine by NOS. All three NOS iso‐
forms are expressed in the lung and are distinguished by regulation of their activities, as
well as by specific sites and developmental patterns of expression [46]. The isoform eNOS is
expressed in vascular endothelial cells and is believed to be the predominant source of NO
production in pulmonary circulation [40]. This hypothesis is corroborated by the fact that
NO inhalation in premature newborns with severe respiratory failure due to PH provides
improvement of symptoms, accompanied by marked increase in oxygenation [34].
Although large well-designed studies paved the way to Food and Drug Administration
(FDA) approval of therapeutic NO inhalation, it is equally important to note that inhaled
NO did not reduce the mortality, length of hospitalization, or the risk of significant neurode‐
velopmental impairment associated with persistent PH in newborn children [40]. It is
known that at excessive levels NO can react with reactive oxygen species (ROS) such as su‐
peroxide and hydrogen peroxide. Such increase in ROS was observed in the smooth muscle
and adventitia of pulmonary arteries from lambs with chronic intrauterine PH [47, 48],
forming peroxynitrite, an anion with deleterious tissue-oxidant effects [49].
Inhaled NO is usually delivered with high concentrations of oxygen. Whereas hyperoxic
ventilation continues to be a mainstay in the treatment of PH, little is  known about the
side effects of oxygen supply together with NO. The extreme hyperoxia routinely used in
PH management may in fact be toxic to the developing lung due to ROS formation [39, 50,
51]. Superoxide may react with arachidonic acid to increase concentrations of isoprostanes
and may also combine with NO to form peroxynitrite [52] with possible induction of vaso‐
constriction, cytotoxicity, and damage to surfactant proteins and lipids. Moreover, peroxy‐
nitrite has been shown to directly induce NOS uncoupling. New data indicate that even
brief (30 min) periods of exposure to 100% O2 are sufficient to increase reactivity of pulmo‐
nary vessels in healthy lambs [53, 54], to diminish the response of the pulmonary vascula‐
ture to endogenous and exogenous nitric oxide [54], and to increase the activity of cGMP-
specific  phosphodiesterases  [51].  Inhaled  NO  would  theoretically  benefit  patients  with
chronic primary or secondary pulmonary hypertension, but its therapeutic application in
this setting has been limited by the risk of causing rebound pulmonary hypertension, if it
is  inadvertently  discontinued,  and the lack of  practical  home-based continuous delivery
devices.
Therefore, we have proposed an alternative approach for controlled induction of NO pro‐
duction. We believe that cytosolic L-arginine provides a major NO donor. Arginine con‐
centrations subject to metabolic fine-tuning controls will assure that the amino acid is kept
in a homeostatic concentration range. These effects could be achieved by the action of Bj-
PRO on AS, a target unexplored by the pharmaceutical industry. Compounds inducing an
increase in AS expression and activity are promising for the treatment of diseases related
with deficient NO production.
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4. Preeclampsia
Preeclampsia, a pregnancy-specific syndrome characterized by hypertension, proteinuria
and edema, causes fetal and maternal morbidity and mortality with high incidence in devel‐
oping countries [55]. Symptoms of preeclampsia are currently combated by sodium restric‐
tion, rest and medication for blood pressure control to avoid complications for the mother
and prolong the pregnancy for fetal maturation [56-58]. However, this attempt is rather un‐
specific with possible side effects for the developing fetus [59, 60]. Currently, the only thera‐
py of preeclamsia involves placenta removal resulting in pre-term birth [61]. Therefore,
novel drug development for pregnancy-specific conditions remains a challenge [59].
The pathology of preeclampsia involves systemic inflammation, oxidative stress, alterations
in the levels of angiogenic factors, and vascular reactivity leading to hypertension of the
mother and metabolic alterations in the fetus [61, 62]. A number of evidence suggests that
clinical manifestations are caused by endothelial malfunction including insufficient produc‐
tion of NO [63, 64]. Levels of eNOS, the enzyme responsible for NO synthesis in the endo‐
thelium from L-arginine, are decreased in human umbilical vein endothelial cells from
pregnant women suffering from preeclampsia [62] together with impaired AS expression
[65]. The low availability of L-arginine uncouples eNOS activity, decreases NO production
and increases eNOS-dependent superoxide generation [62, 66], consequently resulting in re‐
duced vasodilatation or in inflammatory processes observed in preeclampsia [66, 67]. There‐
fore, it is expected that the sustained concentration of L-arginine in endothelial cells is likely
to play a critical role not only in the control of systemic blood pressure, but also in inhibition
of inflammatory processes [68].
Recently, we have reported that a Bj-PRO containing ten amino acid residues (Bj-PRO-10c),
activating AS, is able to correct dysfunction of human umbilical vein endothelial cells from
pregnant women suffering from preeclampsia [65] (Figure 1).
Bj-PRO-10c, besides augmenting the activity of AS both in vitro and in vivo [14] increases sig‐
nificantly eNOS expression of human umbilical vein endothelial cells obtained from preg‐
nant women suffering from preeclampsia [65]. It was observed that the increase in NO
levels induced by Bj-PRO-10c diminished the oxidative stress of the endothelial cells of pree‐
clamptic women, shown as a 50% reduction in superoxide levels [65] (Figure 1).
Most importantly, Bj-PRO-10c promoted NO production only in endothelial cells from pa‐
tients suffering from the disorder and not in normotensive pregnant women. In agreement,
Bj-PRO-10c is a molecule endowed with antihypertensive activity that reduced blood pres‐
sure in hypertensive but not in normotensive rats [69]. These observations led to suggest
that Bj-PRO-10c promotes its anti-hypertensive effect in mothers with preeclampsia without
any effect on the blood pressure of the fetus, a problem with drugs currently used for mini‐
mizing health problems arising from preeclampsia. Taken together, Bj-PRO-10c becomes a
potential tool for the development of an efficient drug for preeclampsia treatment.
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Figure 1. Bj-PRO-10c-induced effects on endothelial cell from healthy and pregnant women suffering from
preeclampsia. In endothelial cells from normotensive pregnant women (NORMAL), NO production is adequate to
maintain normal gestation. In cells from patients with the disease (PREECLAMPSIA) both decreased NO production
and increased superoxide (O2-) production are observed together with enhanced activity of the enzyme arginase, re‐duced expression of eNOS and AS and uncoupled eNOS. When endothelial cells from pregnant women suffering from
preeclampsia are exposed to Bj-PRO-10c (PREECLAMPSIA + Bj-PRO-10c), production of NO and superoxide return to
normal ranges, since Bj-PRO-10c initiates a signaling cascade including increases of cytosolic calcium concentration ac‐
tivating eNOS and augmenting AS activity.
5. Citrullinemia
Citrullinemia, a disorder causing serious episodes of neurological symptoms associated
with hyperammonemia involving disorientation, abnormal behaviors (aggression, irritabili‐
ty, and hyperactivity), seizures, coma, and potentially death from brain edema [70], occurs
in two variants: CTLN1 (MIM#215700) or classical neonatal onset, and CTLN2
(MIM#603471) or adult-onset [71-74]. Classical citrullinemia in children is associated with a
mutation in the AS gene [75]. However, in CTLN2 the enzyme reveals normal kinetic prop‐
erties and is quantitatively deficient only in the liver of adult-onset citrullinemia patients
[71-74]. The most successful therapy of CTLN2 has been liver transplantation [76, 77] be‐
cause this treatment prevents hyperammonemic crises and corrects consequent metabolic
disturbances [70].
It has been reported that administration of L-arginine to CTLN2 patients is effective in de‐
creasing blood ammonia concentration [78, 79]. For ammonia detoxification, arginine needs
to enter the liver via the portal vein where is metabolized by mitochondrial arginase to pro‐
vide ornithine for citrulline and aspartate synthesis and for the priming of the urea cycle
[80]. However, care must be taken when administering L-arginine, as fatal cases caused by
L-arginine hydrochloride overdose have been reported [81]. In general, the dose of L-argi‐
nine supplementation used in the treatment of hyperammoaemia is in the high range be‐
tween 100 and 700 mg/kg body weight per day [82-85]. In animal models the effects of
hyperargininaemia can be observed, reflecting toxic effects of high L-arginine concentration
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and making it possible to predict side effects of L-arginine supplementation including cogni‐
tive deficits, epilepsy and a progressive spastic diplegia [86]. Therefore, drugs augmenting
AS activity, the step-limiting enzyme of urea cycle, may be a promising strategy for CTLN2
therapy, since AS is the step-limiting enzyme of the urea cycle. A consequence of increased
AS activity, a final common pathway is triggered resulting in the excretion of waste nitrogen
as urea [87].
As previously mentioned, CTLN2 is not associated with genetic mutation of the AS gene;
however, Saheki et al. identified the SLC25A13 gene as being defective in CTLN2 patients.
This gene encodes for a Ca2+-dependent mitochondrial solute carrier, designated citrin [88].
According to Saheki et al., it is difficult to predict disease-causing effects of citrin deficiency
in CTLN2, since children carrying citrin gene mutations may suffer from CTLN2 after more
than 10 years or several decades of being asymptomatic [70]. In view of that, an option to
prevent CLTN2 in infants with mutation of the citrin gen is being sought, having in mind
that the nutritional management with appropriate intake of proteins only avoids accumula‐
tion of nitrogen [70].
Based on information discussed here, the strategy to increase AS activity in the liver could
be an effective treatment for CTLN2 as well to prevent that children diagnosed as carrying
SLC25A13 mutations from developing CTLN2 in the future [89]. We believed that direct
pharmacological and clinical studies with Bj-PROs for these proposals, could turn them into
a powerful therapeutic tool. The efficiency of Bj-PRO action can yet be improved by the ra‐
tional design of a compound which in the liver accelerates the urea cycle for eliminating am‐
monia or even preventing its accumulation.
6. Conclusion
AS as molecular target for drug development will be important for the treatment of a wide
variety of diseases associated with deficiency of NO production, and also could transform
Bj-PROs or their synthetic analogous into blockbuster medicine, as happened in the 80s with
Captopril [90, 91]. The properties of Bj-PROs enhancing AS activity [14, 17], provides a pre‐
cise pharmacological tool for controlling pathophysiological mechanisms with advantages
of uncontrolled application of exogenous L-arginine or NO donors [92]. For instance, the ef‐
fect of exogenous NO donors is not subject to physiological control, thus being more suscep‐
tible of generating undesired ROS [93, 94]. For all these reasons, keeping NO production in a
safe level, so that a deleterious threshold would not be reached, is of particular interest. In
this way, Bj-PROs should serve as structural models for the development of therapeutic
agents for the treatment of various diseases related to NO deficiency, as cause or effect, as
well AS deficiency.
Chemical properties of Bj-PROs make these peptides even more attractive potential lead
compounds for drug development. For instance, Bj-PRO-10c is able to penetrate cells, where
it remains as an intact molecule for hours [14]. Moreover, Bj-PROs contain a notable high
proline content [13], which gives them some resistance to hydrolysis by aminopeptidases,
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carboxypeptidases and endopeptidases [95]. Nevertheless, cyclodextrins or nanocompounds
could provide carriers for Bj-PROs, since drug release could be controlled in accordance
with therapeutic propose [96, 97].
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